Citing a dramatic improvement in overall survival in second-line squamous non-small cell lung cancer, FDA rapidly approved the Bristol-Myers Squibb drug Opdivo (nivolumab).
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
